JPWO2020247872A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020247872A5
JPWO2020247872A5 JP2021572049A JP2021572049A JPWO2020247872A5 JP WO2020247872 A5 JPWO2020247872 A5 JP WO2020247872A5 JP 2021572049 A JP2021572049 A JP 2021572049A JP 2021572049 A JP2021572049 A JP 2021572049A JP WO2020247872 A5 JPWO2020247872 A5 JP WO2020247872A5
Authority
JP
Japan
Prior art keywords
antibody
adc
antigen
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021572049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536094A (ja
JP7791716B2 (ja
JP2022536094A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036494 external-priority patent/WO2020247872A1/en
Publication of JP2022536094A publication Critical patent/JP2022536094A/ja
Publication of JPWO2020247872A5 publication Critical patent/JPWO2020247872A5/ja
Publication of JP2022536094A5 publication Critical patent/JP2022536094A5/ja
Priority to JP2025116389A priority Critical patent/JP2025146855A/ja
Application granted granted Critical
Publication of JP7791716B2 publication Critical patent/JP7791716B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2021572049A 2019-06-05 2020-06-05 Ｔ細胞枯渇治療 Active JP7791716B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116389A JP2025146855A (ja) 2019-06-05 2025-07-10 Ｔ細胞枯渇治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962857744P 2019-06-05 2019-06-05
US62/857,744 2019-06-05
PCT/US2020/036494 WO2020247872A1 (en) 2019-06-05 2020-06-05 T-cell depleting therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116389A Division JP2025146855A (ja) 2019-06-05 2025-07-10 Ｔ細胞枯渇治療

Publications (4)

Publication Number Publication Date
JP2022536094A JP2022536094A (ja) 2022-08-12
JPWO2020247872A5 true JPWO2020247872A5 (https=) 2023-06-02
JP2022536094A5 JP2022536094A5 (https=) 2023-06-02
JP7791716B2 JP7791716B2 (ja) 2025-12-24

Family

ID=73652313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572049A Active JP7791716B2 (ja) 2019-06-05 2020-06-05 Ｔ細胞枯渇治療
JP2025116389A Pending JP2025146855A (ja) 2019-06-05 2025-07-10 Ｔ細胞枯渇治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116389A Pending JP2025146855A (ja) 2019-06-05 2025-07-10 Ｔ細胞枯渇治療

Country Status (7)

Country Link
US (1) US20220249683A1 (https=)
EP (1) EP3980034A4 (https=)
JP (2) JP7791716B2 (https=)
CN (1) CN114206358A (https=)
AU (1) AU2020286508A1 (https=)
CA (1) CA3140447A1 (https=)
WO (1) WO2020247872A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3107378A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503887A (ja) * 1988-02-03 1991-08-29 エクソウマ　コーポレーション 自己免疫疾患に対する抗ｔ細胞イムノトキシンの治療的使用
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US20030229207A1 (en) * 1991-12-13 2003-12-11 Xoma Technology Ltd. Modified antibody variable domains
US20060051355A1 (en) * 1998-03-23 2006-03-09 Van Oosterhout Ypke V Methods and means for the treatment of immune-related diseases
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
EP2430051B1 (en) * 2009-05-14 2016-03-23 Institut National de la Santé et de la Recherche Medicale Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
JP6863900B2 (ja) * 2015-03-09 2021-04-21 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規アマトキシン−抗体コンジュゲート
MX395639B (es) * 2017-01-20 2025-03-25 Heidelberg Pharma Res Gmbh Composiciones y métodos para el agotamiento de células cd137+.
CA3079897A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
WO2019108863A1 (en) * 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
SG11202110287QA (en) * 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof

Similar Documents

Publication Publication Date Title
JP7791923B2 (ja) Ｃｄ５＋細胞の枯渇のための組成物および方法
JP7641452B2 (ja) Ｃｄ１１７＋細胞を減少させるための組成物及び方法
US11572411B2 (en) Anti-CD117 antibodies and conjugates
JP7669269B2 (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
JP2025160215A (ja) Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
JP7716399B2 (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
US20200368363A1 (en) Compositions and methods for the depletion of cd2+ cells
JP2025146855A (ja) Ｔ細胞枯渇治療
JP2025172753A (ja) 自己免疫疾患を治療するための方法および組成物
JPWO2021087368A5 (https=)
US20210095039A1 (en) Anti-cd252 antibodies, conjugates, and methods of use
US20210101990A1 (en) Compositions and methods for the depletion of cd134+ cells
JPWO2020247872A5 (https=)